TPWA
BMRN icon

Twin Peaks Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5K Buy
+204
New +$11.9K ﹤0.01% 987
2025
Q3 		– Sell
-229
Closed -$13K – 419
2025
Q2 		$13K Buy
+229
New +$13.5K ﹤0.01% 796

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Peaks Wealth Advisors's BMRN Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 204 shares worth $11.5K. The stake represents ﹤0.01% of the portfolio and ranks #987 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in BMRN as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in BMRN in Q2 2025 and has held it in 2 quarters since. The position peaked at $13K in Q2 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Twin Peaks Wealth Advisors held 204 shares of BioMarin Pharmaceuticals worth $11.5K as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #987 holding.
  • Twin Peaks Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • Twin Peaks Wealth Advisors's BioMarin Pharmaceuticals position peaked at $13K in Q2 2025.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.